Key result
DOACs demonstrate superior efficacy and safety over warfarin in non-valvular atrial fibrillation.
Why the study?
The safety and efficacy of direct acting oral anticoagulants compared with warfarin in patients with non-valvular atrial fibrillation required comprehensive review.
Do direct acting oral anticoagulants improve safety and efficacy compared to warfarin in patients with non-valvular atrial fibrillation?
Do direct acting oral anticoagulants improve safety and efficacy compared to warfarin in patients with non-valvular atrial fibrillation?
Direct oral anticoagulants, especially dabigatran, offer improved safety and efficacy over warfarin in non-valvular atrial fibrillation and post-stenting scenarios.
The review article study the safety and efficacy of using direct acting oral anticoagulants: thrombin inhibitor dabigatran etexilate and inhibitors Xa of the blood clotting factor apixaban, rivaroxaban and edoxaban compared with the vitamin K antagonist warfarin in patients with non-valvular atrial fibrillation. The advantage of direct oral anticoagulants is emphasized. Particular attention is paid in the article to dabigatran etexilate, which demonstrated high efficacy and safety in randomized clinical trials and in actual clinical practice in patients with non-valvular atrial fibrillation. In addition, dabigatran etexilate in the composition of dual antiplatelet therapy in patients with coronary heart disease after stenting of the coronary arteries demonstrated greater safety than triple antithrombotic therapy, which included warfarin. The article shows indications for the use of dabigatran antagonist idaruzizumab and the method of its administration.
No takes yet. Share an insight, caveat, or question.
Е. И. Баранова (2018) conducted a review in non-valvular atrial fibrillation. Direct acting oral anticoagulants (dabigatran, apixaban, rivaroxaban, edoxaban) vs. Warfarin was evaluated. Direct acting oral anticoagulants, particularly dabigatran, demonstrated high efficacy and safety compared with warfarin in patients with non-valvular atrial fibrillation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: